Search
Now showing items 1-10 of 769
A comprehensive model for heat-induced radio-sensitisation.
(2018-06)
Combined radiotherapy (RT) and hyperthermia (HT) treatments may improve treatment outcome by heat induced radio-sensitisation. We propose an empirical cell survival model (AlphaR model) to describe this multimodality ...
Improving the efficiency of breast radiotherapy treatment planning using a semi-automated approach.
(2017-01)
Objectives To reduce treatment planning times while maintaining plan quality through the introduction of semi-automated planning techniques for breast radiotherapy.Methods Automatic critical structure delineation was ...
Impact of F-18-fluciclovine PET/CT on Clinical Management of Patients with Recurrent Prostate Cancer: Results from the Phase 3 FALCON Trial
(ELSEVIER SCIENCE INC, 2017-12-01)
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
(2017-04)
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 ...
New Model for Estimating Glomerular Filtration Rate in Patients With Cancer
(American Society of Clinical Oncology (ASCO), 2017-08-20)
Purpose The glomerular filtration rate (GFR) is essential for carboplatin chemotherapy dosing; however, the best method to estimate GFR in patients with cancer is unknown. We identify the most accurate and least biased ...
Online dose reconstruction for tracked volumetric arc therapy: Real-time implementation and offline quality assurance for prostate SBRT.
(2017-11)
Purpose Firstly, this study provides a real-time implementation of online dose reconstruction for tracked volumetric arc therapy (VMAT). Secondly, this study describes a novel offline quality assurance tool, based on ...
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
(2017-05)
Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ...
Contribution of Common SNPs to Variability in Late Radiation Therapy Toxicity in Prostate Cancer
(ELSEVIER SCIENCE INC, 2017-10-01)